Technology ID
TAB-4473

A Mouse Cell Line Engineered to Produce Camelid Nanobodies for Diagnostic and Therapeutic Use

Co-Inventors
Tessarollo, Lino (NCI)
Xu, Jianliang (NIAMS)
Casellas, Rafael (NIAMS)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Oncology
Infectious Disease
Immunology
Development Stages
Pre-clinical (in vivo)
Research Products
Antibodies
Animal Models
Lead IC
NHLBI
ICs
NIAMS
NCI

This technology includes the development of a mouse line capable of producing single-chain antibodies (nanobodies). Nanobodies, identified initially from Camelidae (including llamas and camels) but also found in cartilaginous fish, consist of a single variable heavy chain domain (VHH) that binds to specific epitopes. Nanobodies have equivalent binding specificity to antigens as antibodies but are more heat- and detergent-stable. The creation of nanobody-producing mice, termed nanomice, has the potential to accelerate the development of nanobodies against infectious diseases and other diagnostic and therapeutic uses.

Commercial Applications
Development of nanobodies against infectious diseases or for basic applications.

Competitive Advantages
Nanobodies can target epitopes that are not normally accessible to conventional antibodies. They can also be readily humanized and appear to be safe and have low immunogenicity in clinical trials.
Licensing Contact:
Knezevic, Vladimir
vlado.knezevic@nih.gov
Phone: (240) 856-0274